The Motley Fool reports that biotech stocks surged in 2025, driven by FDA approvals and a doubling of longevity investment to $8.49 billion.
In 2025 it seemed the only certainty for biotech was more uncertainty. Biotech leaders conducted business as usual against ...
David Reese believes that AI’s greatest impact will come from improving the thousands of human-led decisions. If Reese, the ...
For the third year in a row, Fierce Biotech’s Layoff Tracker is topping the tree as the story with the highest number of reads. The relentless nature of industry layoffs has garnered the most ...
Mr. Dreyer is an American editor and writer who lives in Shanghai. Just outside Shanghai, in the city of Wuxi, China is building its future of medicine — a booming biotechnology hub of factories and ...
Evercore (NYSE:EVR) has hired David Ke as a Senior Managing Director in its equity capital markets group. Ke is an experienced biotechnology investment banker, joining to expand the firm’s ...
Fintel reports that on March 25, 2025, Maxim Group upgraded their outlook for Moleculin Biotech (NasdaqCM:MBRX) from Hold to Buy. As of March 19, 2025, the average one-year price target for Moleculin ...
Hosted on MSN
Jones Trading Downgrades Oncolytics Biotech (ONCY)
Fintel reports that on May 16, 2025, Jones Trading downgraded their outlook for Oncolytics Biotech (NasdaqCM:ONCY) from Buy to Hold. Analyst Price Forecast Suggests 582.90% Upside As of May 7, 2025, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results